Competitive Handbook towards Personalized Medicine in Prostate Cancer

Bioseeker, September 2012, Pages: 1493

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis which allows you to discover:

-Where the competition is; Which targets, compound types and companies are setting the path?

-How much R&D effort has gone towards different targets and what is known about the target?

-Which pathways are targeted, by what and how?

-What is truly new and unique in the prostate cancer pipeline?

-How new and unique your target strategy really is

-What overlapping competition you have from other companies and compound types towards your therapeutic targets

-Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:

1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:
-Head-to-head target competing analysis

-Significant drug target overlap analysis

-Cross-sectional R&D profiling of individual drug targets.

-Cross-over analysis of target strategies among different compound types.

-Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline:
-- Where are we?
-- Where is our general and specific competition?
-- What is the level of competition where we want to be?
-- 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company's interest in the prostate cancer pipeline by:
-Better identifying benchmarking peers

-Providing rationale for in/out licensing decisions of drug candidates

-Performing proper drug due diligence

-Strategies for commercial planning

-Guiding Research & Development efforts

1 Executive Summary

2 About Cancer Highlights™

2.1 Cancer Focus Areas

2.2 Subscribe Today and Start Saving

2.2.1 Type of License

2.3 Additional Information

2.4 BioSeeker Group's Oncology Team

3 Methodology

3.1 Cancer Highlights'™ Five Pillar Drug Assessment

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 Introduction

5.1 The Scope of this Report

5.2 Definitions

5.3 Abbreviations

6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment

6.1 Drug Repositioning in Oncology

6.2 Introduction to Targets of Prostate Cancer Drugs

6.2.1 Acid Phosphatase Activity Targets

6.2.2 Auxiliary Transport Protein Activity Targets

6.2.3 Calcium Ion Binding Targets

6.2.4 Carboxy-lyase Activity Targets

6.2.5 Carboxypeptidase Activity Targets

6.2.6 Catalytic Activity Targets

6.2.7 Cell Adhesion Molecule Activity Targets

6.2.8 Chaperone Activity Targets

6.2.9 Chemokine Activity Targets

6.2.10 Complement Activity Targets

6.2.11 Cysteine-type Peptidase Activity Targets

6.2.12 Cytokine Activity Targets

6.2.13 DNA Binding Targets

6.2.14 DNA Repair Protein Targets

6.2.15 DNA Topoisomerase Activity Targets

6.2.16 DNA-directed DNA Polymerase Activity Targets

6.2.17 Extracellular Ligand-gated Ion Channel Activity Targets

6.2.18 Extracellular Matrix Structural Constituent Targets

6.2.19 G-protein Coupled Receptor Activity Targets

6.2.20 Growth Factor Activity Targets

6.2.21 GTPase Activator Activity Targets

6.2.22 Hormone Activity Targets

6.2.23 Hydrolase Activity Targets

6.2.24 Intracellular Ligand-gated Ion Channel Activity Targets

6.2.25 Ion Channel Activity Targets

6.2.26 Isomerase Activity Targets

6.2.27 Kinase Activity Targets

6.2.28 Ligand-dependent Nuclear Receptor Activity Targets

6.2.29 Ligase Activity Targets

6.2.30 Lipid Kinase Activity Targets

6.2.31 Lipid Phosphatase Activity Targets

6.2.32 Metallopeptidase Activity Targets

6.2.33 MHC Class I Receptor Activity Targets

6.2.34 Molecular Function Unknown Targets

6.2.35 Motor Activity Targets

6.2.36 Oxidoreductase Activity Targets

6.2.37 Peptidase Activity Targets

6.2.38 Peptide Hormone Targets

6.2.39 Peroxidase Activity Targets

6.2.40 Phosphoric Diester Hydrolase Activity Targets

6.2.41 Protein Binding Targets

6.2.42 Protein Serine/Threonine Kinase Activity Targets

6.2.43 Protein Tyrosine Phosphatase Activity Targets

6.2.44 Protein-tyrosine Kinase Activity Targets

6.2.45 Receptor Activity Targets

6.2.46 Receptor Binding Targets

6.2.47 Receptor Signaling Complex Scaffold Activity Targets

6.2.48 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets

6.2.49 RNA Binding Targets

6.2.50 RNA-directed DNA Polymerase Activity Targets

6.2.51 Serine-type Peptidase Activity Targets

6.2.52 Structural Constituent of Cytoskeleton Targets

6.2.53 Superoxide Dismutase Activity Targets

6.2.54 Transcription Factor Activity Targets

6.2.55 Transcription Regulator Activity Targets

6.2.56 Transferase Activity Targets

6.2.57 Translation Regulator Activity Targets

6.2.58 Transmembrane Receptor Activity Targets

6.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

6.2.60 Transporter Activity Targets

6.2.61 Ubiquitin-specific Protease Activity Targets

6.2.62 Voltage-gated Ion Channel Activity Targets

6.2.63 Other Targets

6.3 Mutation Profiles of Prostate Cancer Drug Targets

6.3.1 Targets of Prostate Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

6.4 Prostate Cancer Therapeutics is Stimulated by Available Structure Data on Targets

6.5 Target-Target Interactions among Identified Targets of Prostate Cancer Drugs

6.6 The Drug-Target Competitive Landscape

6.7 Protein Expression Levels of Identified Targets of Prostate Cancer Drugs

6.8 Pathway Assessment of Prostate Cancer Drugs

6.8.1 Tools for Analysis of Cancer Pathways

6.8.2 Pathway Assessment

7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development

7.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Prostate Cancer Drugs

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs

7.5 Preclinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs

7.6 Drug Target Strategies of Suspended or Terminated Prostate Cancer Drugs

7.7 Target Strategy Development Profiles of Prostate Cancer Drugs

7.7.1 Marketed

7.7.2 Pre-registration

7.7.3 Phase III

7.7.4 Phase II

7.7.5 Phase I

7.7.6 Preclinical

7.7.7 No Data

7.7.8 Suspended

7.7.9 Ceased

7.8 The Competition Through Close Mechanistic Approximation of Prostate Cancer Drugs

8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy

8.1 Small Molecules

8.1.1 Background

8.1.2 Target Strategies of Small Molecule Drugs

8.2 Peptide & Protein Drugs

8.2.1 Background

8.2.2 Target Strategies of Peptide and Protein Drugs

8.3 Antibodies

8.3.1 Background

8.3.2 Target Strategies of Antibody Drugs

8.4 Nucleic Acid Therapies

8.4.1 Background

8.4.2 Target Strategies of Nucleic Acid Drugs

8.5 Cell & Gene Therapy

8.5.1 Background

8.5.2 Target Strategies of Cell and Gene Therapy Drugs

8.6 Drug Delivery and Nanotechnology

8.6.1 Background

8.6.2 Target Strategies of Reformulated Drugs

8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator

9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change

9.2 Company Facts and Ranking

9.3 Competitive Fall-Out Assessment

9.4 Abbott

9.5 Active Biotech

9.6 Advantagene

9.7 AEgera

9.8 AEterna Zentaris

9.9 Alchemia

9.10 Alethia Biotherapeutics

9.11 Allos Therapeutics

9.12 AlphaVax

9.13 Alseres Pharmaceuticals

9.14 Altor BioScience

9.15 Ambrilia Biopharma

9.16 American Gene Technology International

9.17 Amgen

9.18 Anavex Life Sciences

9.19 AndroBioSys

9.20 Antisense Pharma

9.21 Antisense Therapeutics

9.22 Antisoma

9.23 Aphios

9.24 ApopLogic Pharmaceuticals

9.25 Apotex

9.26 Aprea

9.27 Ardana

9.28 Ariad

9.29 ArQule

9.30 Array BioPharma

9.31 Ascenta Therapeutics

9.32 Ascepion Pharmaceuticals

9.33 Astellas

9.34 Astex Pharmaceuticals

9.35 AstraZeneca

9.36 Attenuon

9.37 AVI BioPharma

9.38 Bavarian Nordic

9.39 Baxter International

9.40 Bayer

9.41 Bellicum Pharmaceuticals

9.42 Bioenvision

9.43 Biogen Idec

9.44 BioLineRx

9.45 BioMarin

9.46 BioNetWorks

9.47 BioSante

9.48 Biostar

9.49 Boehringer Ingelheim

9.50 Bristol-Myers Squibb

9.51 BTG

9.52 Camurus

9.53 Cancer Research Technology

9.54 Cel-Sci

9.55 Celgene

9.56 Cell Therapeutics

9.57 Celldex Therapeutics

9.58 Celsion

9.59 Center of Molecular Immunology

9.60 Cephalon

9.61 Chemokine Therapeutics

9.62 Circadian Technologies

9.63 Cleveland BioLabs

9.64 Colby

9.65 Cosmo Bioscience

9.66 Curaxis

9.67 Curis

9.68 Cylene Pharmaceuticals

9.69 Cytokinetics

9.70 Daiichi Sankyo

9.71 Debiopharm

9.72 Dendreon

9.73 Dongkook Pharm

9.74 ECI

9.75 Eisai

9.76 Eli Lilly

9.77 Endo Pharmaceuticals

9.78 Endocyte

9.79 Ensemble Discovery

9.80 EntreMed

9.81 EpiCept

9.82 Esperance Pharmaceuticals

9.83 Etubics

9.84 EUSA Pharma

9.85 Exelixis

9.86 Ferring

9.87 Formula Pharmaceuticals

9.88 Galena Biopharma

9.89 Gemin X Pharmaceuticals

9.90 Generex

9.91 GENova Biotherapeutics

9.92 Genovax

9.93 Genta

9.94 Gerolymatos

9.95 Geron

9.96 Gilead Sciences

9.97 GlaxoSmithKline

9.98 GlycoGenesys

9.99 Got-a-Gene

9.100 GP Pharm

9.101 Green Cross

9.102 GTx

9.103 Harbor BioSciences

9.104 Hoffmann-La Roche

9.105 Human Genome Sciences

9.106 IGF Oncology

9.107 Immunocore

9.108 ImmunoGen

9.109 Immunomedics

9.110 ImmuPharma

9.111 Incyte Corporation

9.112 Infinity Pharmaceuticals

9.113 Inovio

9.114 Insmed

9.115 Insys Therapeutics

9.116 Introgen Therapeutics

9.117 Ipsen

9.118 Isis Pharmaceuticals

9.119 Ivy Medical Chemicals

9.120 Johnson & Johnson

9.121 Karo Bio

9.122 Kinex

9.123 Kyowa Hakko Kirin

9.124 Leo

9.125 Ligand

9.126 Lorus Therapeutics

9.127 Mannkind

9.128 Marillion Pharmaceuticals

9.129 Med Discovery

9.130 Meda

9.131 Medarex

9.132 MediGene

9.133 MedImmune

9.134 Mediolanum

9.135 Medivation

9.136 Menarini

9.137 Merck & Co

9.138 Merck KGaA

9.139 Merrion Pharmaceuticals

9.140 MethylGene

9.141 Mojave Therapeutics

9.142 Molecular Insight

9.143 Nektar Therapeutics

9.144 Nereus Pharmaceuticals

9.145 Nerviano Medical Sciences

9.146 Neurocrine Biosciences

9.147 Nippon Shinyaku

9.148 Non-industrial Sources

9.149 Northwest Biotherapeutics

9.150 Novacea

9.151 Novartis

9.152 Novogen

9.153 Oasmia

9.154 OncoGenex Pharmaceuticals

9.155 Oncothyreon

9.156 Oncovir

9.157 Orion Pharma

9.158 OSI Pharmaceuticals

9.159 Oxford BioMedica

9.160 Paladin Labs

9.161 Pantarhei Bioscience

9.162 Pepscan Therapeutics

9.163 Pfizer

9.164 Pharmacyclics

9.165 PharmaGap

9.166 PharmaMar

9.167 Philogen

9.168 Pierre Fabre

9.169 Progen

9.170 Progenics Pharmaceuticals

9.171 ProNAi Therapeutics

9.172 ProStrakan

9.173 Q Chip

9.174 QLT

9.175 Receptor BioLogix

9.176 Regeneron

9.177 Regulon

9.178 Rexahn

9.179 Salzburg Therapeutics

9.180 Samyang

9.181 Sanofi

9.182 Santaris Pharma

9.183 Sapphire Therapeutics

9.184 SBIO

9.185 SeleXel

9.186 Semafore Pharmaceuticals

9.187 Serometrix

9.188 SGX Pharmaceuticals

9.189 Shire

9.190 Siena Biotech

9.191 Soligenix

9.192 Sophiris Bio

9.193 SRI International

9.194 Supratek Pharma

9.195 Switch Pharma

9.196 Synta Pharmaceuticals

9.197 Taiho

9.198 Takeda

9.199 Tapestry Pharmaceuticals

9.200 Tau Therapeutics

9.201 Teva

9.202 Thallion Pharmaceuticals

9.203 Therion Biologics

9.204 Titan Pharmaceuticals

9.205 Tokai Pharmaceuticals

9.206 TopoTarget

9.207 Tracon Pharmaceuticals

9.208 Transgene

9.209 Twinstrand Therapeutics

9.210 Unigene

9.211 United Biomedical

9.212 Vaxon Biotech

9.213 Velacor Therapeutics

9.214 Vical

9.215 Vion Pharmaceuticals

9.216 VioQuest

9.217 Viralytics

9.218 ViroTarg

9.219 VM Discovery

9.220 Wilex

9.221 Xerion

9.222 Xoma

9.223 YM BioSciences

9.224 Zydus Cadila

10 Disclaimer

11 Drug Index

12 Company Index

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Prostate Cancer Drugs

Figure 2: The Drug-Target Competitive Landscape of Prostate Cancer Drugs - Larger Clusters

Figure 3: The Drug-Target Competitive Landscape Prostate Cancer Drugs - Smaller Clusters

Figure 4: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs – Larger Clusters

Figure 5: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs – Smaller Clusters

Figure 6: Distribution of Compound Strategies among Prostate Cancer Drugs

Figure 7: Primary Sub-cellular Localization of Drug Targets

Figure 8: Number of Companies per Ranking Level

4.2 List of Tables
Table 1: Cancer Highlights'™ Five Pillar Drug Assessment

Table 2: Breakdown of the Included Prostate Cancer Drug Pipeline by Stage of Development

Table 3: Head to Head Target Competition among Prostate Cancer Drugs

Table 4: Overview of Drug Target Strategy Themes

Table 5: Terminally Ceased Targets of Prostate Cancer Drugs

Table 6: Official Gene Symbol to Target Profle

Table 7: Mutation Frequencies of Prostate Cancer Drug Targets

Table 8: Identity of Drug Targets with Available Biological Structures

Table 9: Number of Target-Target Interactions among Targets of Prostate Cancer Drugs

Table 10: Available Protein Expression Profiles of Prostate Cancer Drug Targets

Table 11: Pathway Summary

Table 12: Drug Targets without any Identified Assigned Pathways

Table 13: Pathway Profiles According to BioCarta of Prostate Cancer Drug Targets

Table 14: Pathway Profiles According to KEGG of Prostate Cancer Drug Targets

Table 15: Pathway Profiles According to NetPath of Prostate Cancer Drug Targets

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness

Table 17: Top Competitive Target Strategies of Prostate Cancer Drugs

Table 18: New and Unique Target Strategies of Prostate Cancer Drugs in Pre-registration or on the Marketed

Table 19: The Competition Through Close Mechanistic Approximation Between Prostate Cancer Drugs Being Marketed

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Prostate Cancer Drugs

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Prostate Cancer Drugs

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Prostate Cancer Drugs

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Prostate Cancer Drugs

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Prostate Cancer Drugs

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Prostate Cancer Drugs

Table 26: New and Unique Target Strategies in Preclinical Development of Prostate Cancer Drugs

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Prostate Cancer Drugs

Table 28: Target Strategies of No Data, Suspended or Terminated Prostate Cancer Drugs

Table 29: Connecting Target Strategy with Its Profile Identification Number

Table 30: The Competition Through Close Mechanistic Approximation Among Prostate Cancer Drugs

Table 31: Overview of Compound Strategy Competition Among Prostate Cancer Drugs

Table 32: Overview of the Competitive Landscape of Small Molecule Based Prostate Cancer Drugs

Table 33: Competitive Comparison of Target Strategies of Small Molecule Prostate Cancer Drugs

Table 34: Pursued Target Strategies of Small Molecule Drugs Based Prostate Cancer Drugs

Table 35: Overview of the Competitive Landscape of Peptide Based Prostate Cancer Drugs

Table 36: Competitive Comparison of Target Strategies of Peptide Based Prostate Cancer Drugs

Table 37: Pursued Target Strategies of Peptide Based Prostate Cancer Drugs

Table 38: Overview of the Competitive Landscape of Protein Based Prostate Cancer Drugs

Table 39: Competitive Comparison of Target Strategies of Protein Based Prostate Cancer Drugs

Table 40: Pursued Target Strategies of Protein Based Prostate Cancer Drugs

Table 41: Overview of the Competitive Landscape of Antibody Based Prostate Cancer Drugs

Table 42: Competitive Comparison of Target Strategies of Antibody Based Prostate Cancer Drugs

Table 43: Pursued Target Strategies of Antibody Based Prostate Cancer Drugs

Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Prostate Cancer Drugs

Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Prostate Cancer Drugs

Table 46: Pursued Target Strategies of Nucleic Acid Based Prostate Cancer Drugs

Table 47: Potential Forms of Cell Therapy

Table 48: Vectors in Gene Therapy

Table 49: Overview of the Competitive Landscape of Cell Therapy Based Prostate Cancer Drugs

Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Prostate Cancer Drugs

Table 51: Pursued Target Strategies of Cell Therapy Based Prostate Cancer Drugs

Table 52: Overview of the Competitive Landscape of Gene Therapy Based Prostate Cancer Drugs

Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Prostate Cancer Drugs

Table 54: Pursued Target Strategies of Gene Therapy Based Prostate Cancer Drugs

Table 55:Overview of the Competitive Landscape of Reformulated Prostate Cancer Drugs

Table 56: Competitive Comparison of Target Strategies of Reformulated Prostate Cancer Drugs

Table 57: Pursued Target Strategies of Reformulated Prostate Cancer Drugs

Table 58: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets

Table 59: Competitive Summary by Investigator of Prostate Cancer Drug Development

Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Prostate Cancer Drug Development

Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters

Table 62: Example of a Competitive Fall-Out Table (Targeting TOP2A)

Table 63: Abbott's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 64: Active Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 65: Advantagene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 66: AEgera's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 67: AEterna Zentaris' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 68: Alchemia's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 69: Alethia Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 70: Allos Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 71: AlphaVax's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 72: Alseres Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 73: Altor BioScience's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 74: Ambrilia Biopharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 75: American Gene Technology International's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 76: Amgen's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 77: Anavex Life Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 78: AndroBioSys' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 79: Antisense Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 80: Antisense Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 81: Antisoma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 82: Aphios' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 83: ApopLogic Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 84: Apotex's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 85: Aprea's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 86: Ardana's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 87: Ariad's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 88: ArQule's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 89: Array BioPharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 90: Ascenta Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 91: Ascepion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 92: Astellas' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 93: Astex Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 94: AstraZeneca's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 95: Attenuon's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 96: AVI BioPharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 97: Bavarian Nordic's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 98: Baxter International's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 99: Bayer's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 100: Bellicum Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 101: Bioenvision's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 102: Biogen Idec's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 103: BioLineRx's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 104: BioMarin's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 105: BioNetWorks' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 106: BioSante's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 107: Biostar's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 108: Boehringer Ingelheim's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 109: Bristol-Myers Squibb's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 110: BTG's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 111: Camurus' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 112: Cancer Research Technology's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 113: Cel-Sci's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 114: Celgene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 115: Cell Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 116: Celldex Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 117: Celsion's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 118: Center of Molecular Immunology's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 119: Cephalon's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 120: Chemokine Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 121: Circadian Technologies' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 122: Cleveland BioLabs' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 123: Colby's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 124: Cosmo Bioscience's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 125: Curaxis' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 126: Curis' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 127: Cylene Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 128: Cytokinetics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 129: Daiichi Sankyo's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 130: Debiopharm's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 131: Dendreon's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 132: Dongkook Pharm's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 133: ECI's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 134: Eisai's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 135: Eli Lilly's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 136: Endo Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 137: Endocyte's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 138: Ensemble Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 139: EntreMed's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 140: EpiCept's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 141: Esperance Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 142: Etubics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 143: EUSA Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 144: Exelixis' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 145: Ferring's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 146: Formula Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 147: Galena Biopharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 148: Gemin X Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 149: Generex's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 150: GENova Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 151: Genovax's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 152: Genta's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 153: Gerolymatos' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 154: Geron's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 155: Gilead Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 156: GlaxoSmithKline's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 157: GlycoGenesys' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 158: Got-a-Gene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 159: GP Pharm's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 160: Green Cross' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 161: GTx's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 162: Harbor BioSciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 163: Hoffmann-La Roche's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 164: Human Genome Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 165: IGF Oncology's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 166: Immunocore's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 167: ImmunoGen's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 168: Immunomedics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 169: ImmuPharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 170: Incyte Corporation's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 171: Infinity Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 172: Inovio's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 173: Insmed's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 174: Insys Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 175: Introgen Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 176: Ipsen's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 177: Isis Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 178: Ivy Medical Chemicals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 179: Johnson & Johnson's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 180: Karo Bio's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 181: Kinex's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 182: Kyowa Hakko Kirin's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 183: Leo's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 184: Ligand's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 185: Lorus Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 186: Mannkind's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 187: Marillion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 188: Med Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 189: Meda's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 190: Medarex's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 191: MediGene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 192: MedImmune's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 193: Mediolanum's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 194: Medivation's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 195: Menarini's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 196: Merck & Co's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 197: Merck KGaA's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 198: Merrion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 199: MethylGene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 200: Mojave Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 201: Molecular Insight's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 202: Nektar Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 203: Nereus Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 204: Nerviano Medical Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 205: Neurocrine Biosciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 206: Nippon Shinyaku's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 207: Non-industrial source's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 208: Northwest Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 209: Novacea's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 210: Novartis' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 211: Novogen's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 212: Oasmia's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 213: OncoGenex Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 214: Oncothyreon's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 215: Oncovir's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 216: Orion Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 217: OSI Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 218: Oxford BioMedica's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 219: Paladin Labs' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 220: Pantarhei Bioscience's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 221: Pepscan Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 222: Pfizer's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 223: Pharmacyclics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 224: PharmaGap's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 225: PharmaMar's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 226: Philogen's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 227: Pierre Fabre's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 228: Progen's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 229: Progenics Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 230: ProNAi Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 231: ProStrakan's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 232: Q Chip's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 233: QLT's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 234: Receptor BioLogix's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 235: Regeneron's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 236: Regulon's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 237: Rexahn's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 238: Salzburg Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 239: Samyang's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 240: Sanofi's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 241: Santaris Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 242: Sapphire Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 243: SBIO's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 244: SeleXel's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 245: Semafore Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 246: Serometrix's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 247: SGX Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 248: Shire's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 249: Siena Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 250: Soligenix's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 251: Sophiris Bio's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 252: SRI International's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 253: Supratek Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 254: Switch Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 255: Synta Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 256: Taiho's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 257: Takeda's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 258: Tapestry Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 259: Tau Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 260: Teva's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 261: Thallion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 262: Therion Biologics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 263: Titan Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 264: Tokai Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 265: TopoTarget's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 266: Tracon Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 267: Transgene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 268: Twinstrand Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 269: Unigene's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 270: United Biomedical's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 271: Vaxon Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 272: Velacor Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 273: Vical's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 274: Vion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 275: VioQuest's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 276: Viralytics' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 277: ViroTarg's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 278: VM Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 279: Wilex's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 280: Xerion's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 281: Xoma's Included Prostate Cancer Drugs and Competitive Fall-Out

Table 282: YM BioSciences' Included Prostate Cancer Drugs and Competitive Fall-Out

Table 283: Zydus Cadila's Included Prostate Cancer Drugs and Competitive Fall-Out

- Abbott
- Active Biotech
- Advantagene
- Egera
- Eterna Zentaris
- lchemia
- Alethia Biotherapeutics
- Allos Therapeutics
- AlphaVax
- Alseres Pharmaceuticals
- Altor BioScience
- Ambrilia Biopharma
- American Gene Technology International
- Amgen
- Anavex Life Sciences
- AndroBioSys
- Antisense Pharma
- Antisense Therapeutics
- Antisoma
- Aphios
- ApopLogic Pharmaceuticals
- Apotex
- Aprea
- Ardana
- Ariad
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Ascepion Pharmaceuticals
- Astellas
- Astex Pharmaceuticals
- AstraZeneca
- Attenuon
- AVI BioPharma
- Bavarian Nordic
- Baxter International
- Bayer
- Bellicum Pharmaceuticals
- Bioenvision
- Biogen Idec
- BioLineRx
- BioMarin
- BioNetWorks
- BioSante
- Biostar
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Camurus
- Cancer Research Technology
- Cel-Sci
- Celgene
- Cell Therapeutics
- Celldex Therapeutics
- Celsion
- Center of Molecular Immunology
- Cephalon
- Chemokine Therapeutics
- Circadian Technologies
- Cleveland BioLabs
- Colby
- Cosmo Bioscience
- Curaxis
- Curis
- Cylene Pharmaceuticals
- Cytokinetics
- Daiichi Sankyo
- Debiopharm
- Dendreon
- Dongkook Pharm
- ECI
- Eisai
- Eli Lilly
- Endo Pharmaceuticals
- Endocyte
- Ensemble Discovery
- EntreMed
- EpiCept
- Esperance Pharmaceuticals
- Etubics
- EUSA Pharma
- Exelixis
- Ferring
- Formula Pharmaceuticals
- Galena Biopharma
- Gemin X Pharmaceuticals
- Generex
- GENova Biotherapeutics
- Genovax
- Genta
- Gerolymatos
- Geron
- Gilead Sciences
- GlaxoSmithKline
- GlycoGenesys
- Got-a-Gene
- GP Pharm
- Green Cross
- GTx
- Harbor BioSciences
- Hoffmann-La Roche
- Human Genome Sciences
- IGF Oncology
- Immunocore
- ImmunoGen
- Immunomedics
- ImmuPharma
- Incyte Corporation
- Infinity Pharmaceuticals
- Inovio
- Insmed
- Insys Therapeutics
- Introgen Therapeutics
- Ipsen
- Isis Pharmaceuticals
- Ivy Medical Chemicals
- Johnson & Johnson
- Karo Bio
- Kinex
- Kyowa Hakko Kirin
- Leo
- Ligand
- Lorus Therapeutics
- Mannkind
- Marillion Pharmaceuticals
- Med Discovery
- Meda
- Medarex
- MediGene
- MedImmune
- Mediolanum
- Medivation
- Menarini
- Merck & Co
- Merck KGaA
- Merrion Pharmaceuticals
- MethylGene
- Mojave Therapeutics
- Molecular Insight
- Nektar Therapeutics
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- Neurocrine Biosciences
- Nippon Shinyaku
- Non-industrial Sources
- Northwest Biotherapeutics
- Novacea
- Novartis
- Novogen
- Oasmia
- OncoGenex Pharmaceuticals
- Oncothyreon
- Oncovir
- Orion Pharma
- OSI Pharmaceuticals
- Oxford BioMedica
- Paladin Labs
- Pantarhei Bioscience
- Pepscan Therapeutics
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Philogen
- Pierre Fabre
- Progen
- Progenics Pharmaceuticals
- ProNAi Therapeutics
- ProStrakan
- Q Chip
- QLT
- Receptor BioLogix
- Regeneron
- Regulon
- Rexahn
- Salzburg Therapeutics
- Samyang
- Sanofi
- Santaris Pharma
- Sapphire Therapeutics
- SBIO
- SeleXel
- Semafore Pharmaceuticals
- Serometrix
- SGX Pharmaceuticals
- Shire
- Siena Biotech
- Soligenix
- Sophiris Bio
- SRI International
- Supratek Pharma
- Switch Pharma
- Synta Pharmaceuticals
- Taiho
- Takeda
- Tapestry Pharmaceuticals
- Tau Therapeutics
- Teva
- Thallion Pharmaceuticals
- Therion Biologics
- Titan Pharmaceuticals
- Tokai Pharmaceuticals
- TopoTarget
- Tracon Pharmaceuticals
- Transgene
- Twinstrand Therapeutics
- Unigene
- United Biomedical
- Vaxon Biotech
- Velacor Therapeutics
- Vical
- Vion Pharmaceuticals
- VioQuest
- Viralytics
- ViroTarg
- VM Discovery
- Wilex
- Xerion
- Xoma
- YM BioSciences
- Zydus Cadila

Customers who bought this item also bought

• Cancer Vaccines: From First-in-Class to Best-in-Class?
• Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)
• Prostate Cancer (Event Driven)
• Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2012
• Prostate Cancer Partnering 2007-2013
• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
• Metastatic Prostate Cancer - Pipeline Review, H2 2012
• Personalized Medicine - Scientific and Commercial Aspects
• Prostate Cancer - Germany Drug Forecasts and Treatment Analysis to 2020
• Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020